Download - Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more

Discover

Podcast Features
Your all-in-one podcasting solution.

Blog to Podcast
Turn your blog into an engaging podcast.
Livestream
High-performing audio live, without limits.

Podcast Studio
Easy-to-use audio recorder app.
Podbean AI
AI-Enhanced Audio Quality and Content Generation.

Podcast App
The best podcast player & podcast app.

Ads Marketplace
Join Ads Marketplace to earn money
through sponsorship on your podcast.

PodAds
Manage your ads with dynamic ad insertion capability.
Apple Podcasts Subscriptions Integration
Effortlessly publish and manage exclusive episodes for your
Apple Podcasts subscribers directly from Podbean.
Live Streaming
Receive livestream rewards from your audience and earn
recurring income from your Fan Club membership.

All Arts Business Comedy Education
Fiction Government Health & Fitness History Kids & Family
Leisure Music News Religion & Spirituality Science
Society & Culture Sports Technology True Crime TV & Film
Live

How to Start a Podcast
How to Start a Live Podcast
How to Monetize a podcast
How to Promote Your Podcast
How to Use Group Recording

Log in
Start your podcast for free

Podcasting
Monetization
Advertisers
Enterprise
Pricing
Discover

VJHemOnc Podcast

Health & Fitness:Medicine

Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more

2024-07-01

Download

In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, who will discuss combinations of BTK and BCL2 inhibitors, the efficacy of BTK degraders in CLL, and the role of epcoritamab in the treatment of RT.